VALBIOTIS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.89 EUR | -1.27% |
|
-3.23% | -22.20% |
| Apr. 26 | Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 03 | Valbiotis: launch of Valbiotis PRO Cholesterol in May | CF |
| Sales 2024 * | 11M 11.93M | Sales 2025 * | 24.13M 26.17M | Capitalization | 61.38M 66.57M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M -6.51M | Net income 2025 * | 3M 3.25M | EV / Sales 2024 * | 3.93 x |
| Net cash position 2024 * | 18.13M 19.67M | Net cash position 2025 * | 34.17M 37.05M | EV / Sales 2025 * | 1.13 x |
| P/E ratio 2024 * |
-4.42
x | P/E ratio 2025 * |
48.6
x | Employees | 52 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.94% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.27% | ||
| 1 week | -3.23% | ||
| 1 month | -5.35% | ||
| 3 months | -5.81% | ||
| 6 months | -25.19% | ||
| Current year | -22.20% |
1 week
3.85
4.06
1 month
3.854.73
Current year
3.415.30
1 year
3.417.50
3 years
2.827.50
5 years
1.988.38
10 years
1.9810.65
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
Pascal Sirvent
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Sébastien Bessy
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Agnès Tixier
BRD | Director/Board Member | - | 19-03-17 |
Laurent Lévy
CHM | Chairman | 53 | 17-02-28 |
| Chief Executive Officer | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 3.89 | -1.27% | 20,218 |
| 24-05-30 | 3.94 | +1.03% | 28,118 |
| 24-05-29 | 3.9 | -0.64% | 29,625 |
| 24-05-28 | 3.925 | -0.76% | 40,170 |
| 24-05-27 | 3.955 | -1.62% | 19,575 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT
More quotes
VALBIOTIS is a French Research & Development company committed to scientific innovation for the prevention and control of metabolic diseases. VALBIOTIS specializes in the development of innovative nutritional solutions for cardio-metabolic disease prevention and nutritional support for patients. The products are intended for food and pharmaceutical industries. VALBIOTIS is essentially intervening in the prevention of type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and cardiovascular diseases.
VALBIOTIS has established numerous partnerships with academic centers of excellence in France and overseas, including the University of La Rochelle, the CNRS, and the Clermont Auvergne University in Clermont-Ferrand where the company has opened a secondary school. With these agreements, since its inception VALBIOTIS has benefited from a strong leverage thanks notably to experts and technical partners involved in its projects.
Calendar
2024-06-24
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.89
EUR
Average target price
10.07
EUR
Spread / Average Target
+158.78%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.20% | 66.57M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- ALVAL Stock
